B
27.36
-0.58 (-2.08%)
| Previous Close | 27.94 |
| Open | 28.22 |
| Volume | 430,191 |
| Avg. Volume (3M) | 909,748 |
| Market Cap | 2,265,561,344 |
| Price / Sales | 6.18 |
| Price / Book | 2.76 |
| 52 Weeks Range |
| Profit Margin | -41.07% |
| Operating Margin (TTM) | -746.40% |
| Diluted EPS (TTM) | -1.58 |
| Quarterly Revenue Growth (YOY) | -17.00% |
| Total Debt/Equity (MRQ) | 20.48% |
| Current Ratio (MRQ) | 5.69 |
| Operating Cash Flow (TTM) | -135.81 M |
| Levered Free Cash Flow (TTM) | -38.55 M |
| Return on Assets (TTM) | -9.27% |
| Return on Equity (TTM) | -18.29% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Beam Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
-0.5
| Analyst Consensus | -0.5 |
| Insider Activity | 0.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.48% |
| % Held by Institutions | 93.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mwg Management Ltd. | 30 Sep 2024 | 2,266,934 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 192.40%) | Buy |
| Median | 31.50 (15.13%) | |
| Low | 24.00 (RBC Capital, -12.28%) | Hold |
| 24.00 (Scotiabank, -12.28%) | Hold | |
| Average | 41.75 (52.60%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 26.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Dec 2024 | 80.00 (192.40%) | Buy | 27.52 |
| 07 Nov 2024 | 80.00 (192.40%) | Buy | 26.10 | |
| Leerink Partners | 06 Nov 2024 | 39.00 (42.54%) | Buy | 26.62 |
| RBC Capital | 06 Nov 2024 | 24.00 (-12.28%) | Hold | 26.62 |
| Scotiabank | 16 Oct 2024 | 24.00 (-12.28%) | Hold | 26.69 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BELLON CHRISTINE | - | 24.70 | -1,241 | -30,653 |
| CAVANAGH BETHANY J | - | 24.70 | -1,117 | -27,590 |
| EMANY SRAVAN KUMAR | 24.80 | - | 80,000 | 1,984,000 |
| Aggregate Net Quantity | 77,642 | |||
| Aggregate Net Value ($) | 1,925,757 | |||
| Aggregate Avg. Buy ($) | 24.80 | |||
| Aggregate Avg. Sell ($) | 24.70 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CAVANAGH BETHANY J | Officer | 02 Jan 2025 | Automatic sell (-) | 1,117 | 24.70 | 27,590 |
| BELLON CHRISTINE | Officer | 02 Jan 2025 | Automatic sell (-) | 1,241 | 24.70 | 30,653 |
| EMANY SRAVAN KUMAR | Officer | 31 Dec 2024 | Acquired (+) | 80,000 | 24.80 | 1,984,000 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |